Table 1

Summary of tests to be considered for a contemporary state-of-the art Optic Neuritis Treatment Trial

Clinical	Patient reported	Imaging	Laboratory	Other
HCVA	QoL	Funduscopy	MOG*	ERG†
LCVA	PROMs	OCT‡	AQP4*	VEP†
Colour vision	Service requirements	OCTA§	ANA	Perimetry
Pulfrich	Ease of service access	FAF†	Neurofilament¶	Pharmacokinetics
RAPD**	Satisfaction	MRI††	Sample storage

We strongly recommend storage of research blood samples as new biomarkers continue to be discovered.
*Cell-based assays recommended for MOG and AQP4.
†On clinical grounds, in selected cases, FAF/ERG/VEP will be very helpful. We do not think this needs to be done routinely in every patient.
‡We recommend a macular volume scan of sufficient quality to permit layer segmentation and recognition of MMO and a peripapillary ring scan. Adherence to validated OCT quality control criteria and reporting guidelines is recommended.22 ,61 There should be a central reading centre.64
§Same macular area as by OCT; optic disc only if device capable to reliably image.
¶Neurofilament light and heavy chains should be quantified using a sensitive and validated immunoassay; batch analyses in single laboratory strongly recommended.
**Quantitative, pupillometric assessment of the RAPD.29 [68]
††MRI sequences have been detailed in a consensus protocol.6 This protocol takes ~10 min for the optic nerve, ~20 min for the brain and, if required, an additional ~15 min for the spinal cord. Inclusion of research sequences such as diffusion tensor imaging will require more time.
ANA, antinuclear antibodies; AQP4, aquaporin 4; ERG, electroretinogram; FAF, fluorescein angiography; HCVA, high-contrast visual acuity; LCVA, low-contrast visual acuity; MOG, myelin oligodendrocyte; OCT, optical coherence tomography; OCTA, optical coherence tomography angiography; PROM, patient-reported outcome measure; QoL, quality of life; RAPD, relative afferent pupillary deficit; VEP, visual evoked potentials.